Best of AC17 Session - Hematopoietic Stem Cell Transplantation

    • List Price: $35.00
    • Member Price: $25.00

Update on Maintenance Chemotherapy Post Hematopoietic Stem Cell Transplantation

In-high risk patients, maintenance therapy following transplantation improves progression-free and overall survival. Discussion will include both the identification of high-risk patients who would benefit from maintenance therapy and the optimal timing for initiation of posttransplant treatment. This presentation will address the current role of maintenance therapy in patients with multiple myeloma, lymphoma, and leukemia and will target both beginning and advanced practitioners.


Content Area: Patient Management & Therapeutics

Pharmacotherapeutic Considerations in T-Cell Replete Haploidentical Stem Cell Transplantation

This session will review the various approaches currently being used in T-cell replete haploidentical SCT. We will review the various conditioning regimens being used as well as supportive care given in T-cell replete SCT. Supportive care unique to this platform includes attention to infectious complications, organ toxicity, and dosing of conditioning chemotherapy. Also, the evidence supporting the use of this type of transplant in comparison to matched related and unrelated transplant as well as umbilical cord transplant will be explored. The BMT pharmacist should be aware of considerations in infectious disease prophylaxis, therapeutic drug monitoring, and supportive care.


Content Area: Patient Management & Therapeutics


Product Details:

Session from the HOPA 2017 Annual Conference

Update on Maintenance Chemotherapy Post Hematopoietic Stem Cell Transplantation

Speaker: Sarah Perreault, PharmD BCOP BCPS

Learning Objectives:

1.      Review the current recommendations for maintenance therapy in multiple myeloma...

Show More
There are not any reviews for this product.
Contains 0 items
Subtotal: $0.00